Zinc Pyrithione and its use in Cosmetic Products
Zinc and its salts are often use in the cosmetic industry. Zinc Pyrithione, in particular, is used as an anti-dandruff in rinse-off cosmetic products. But is this ingredient considered safe by the SCCS?

ZINC AND ZINC PYRITHIONE

Zinc is a trace mineral, vital to the human body and all forms of life, having catalytic, structural and regulatory functions. Nevertheless, high levels of dietary zinc can cause anemia, decreased absorption levels of copper and iron, and reduction of enzyme activities in several tissues. In 2003, the Scientific Committee on Food (SCF) established a tolerable total uptake level (UL) of Zinc up to 25 mg.

In the cosmetic industry, Zinc and zinc salts are used in a variety of categories. Cosmetic products might account for maximum 10% of the UL. One of the most widely used zinc salt is Zinc Pyrithione. It is an aromatic zinc compound used as an antidandruff, antiseborrhoeic, hair conditioning agent and preservative in cosmetics and personal care products. This compound has been used for more than 60 years as an anti-dandruff agent in concentration up to 1-2%.

In the European Union (EU), in accordance with the European Cosmetic Regulation No. 1223/2009,, Zinc Pyrithione is included in the list of substances which cosmetic products must not contain except subject to the restrictions laid down (Annex III). According to same Regulation, Zinc Pyrithione is also included in the Annex V (list of preservatives allowed in cosmetic products), and may be used as a preservative in rinse-off products (excluding oral hygiene products) in a concentration up to 1% in hair products and 0.5% in other products (Annex V/8).

The U.S. Food and Drug Administration (FDA) allows the use of Zinc Pyrithione as an active ingredient in Over-The-Counter (OTC) dandruff and seborrheic dermatitis drug products.

SCCS OPINION ON ZINC PYRITHIONE

The European Scientific Committee on Consumer Safety (SCCS) has expressed its opinion (March 2020) regarding the safety of Zinc Pyrithione (ZPT) in cosmetic products. The SCCS concluded that Zinc Pyrithione was “safe when used as an anti-dandruff in rinse-off hair products up to a maximum concentration of 1%”. This opinion updated a previous SCCS opinion (2013), that stated that this ingredient was safe up to 2% as an antidandruff agent in rinse-off products.

In 2018, ECHA’s Risk Assessment Committee (RAC) issued an opinion proposing harmonized classification and labelling at EU level of Zinc Pyrithione as a CMR 1B substance under Regulation (EC) No. 1272/2008 (presumed human carcinogen, mutagen or reproductive toxicant based on animal studies). According to this Regulation, the use of this type of substances shall be prohibited in cosmetic products, unless, by way of exception, specific conditions are fulfilled.

Zinc Pyrithione was at least a mild skin irritant to human volunteers and it was a severe eye irritant in animal studies. This compound was not a skin sensitizer when tested in guinea pigs and it demonstrated a low potential to induce contact hypersensitivity in humans, when tested alone or in cosmetic formulations. Zinc Pyrithione is neither genotoxic nor mutagenic in vivo and in vitro. It showed no evidence of carcinogenic potential in chronic oral and dermal studies.

In sum, Zinc Pyrithione is considered safe by the SCCS and may be used in cosmetic products made available in the EU market, but only if used up to 1% in rinse-off products. If you need further support understanding Zinc Pyrithione limits applicable to your products, feel free to contact us at info@criticalcatalyst.com.

References:

  1. European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA) – Scientific Opinion on Dietary Reference Values for Zinc, 2014. Available at: https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2014.3844
  2. Joint FAO/WHO Expert Committee on Food Additives (JECFA) – Zinc. Available at: https://apps.who.int/food-additives-contaminants-jecfa-database/chemical.aspx?chemID=4197
  3. Scientific Committee on Consumer Safety (SCCS) – Opinion on Zinc Pyrithione (ZPT), 2019. Available at: https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_236.pdf

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »